Royalty Report: Drugs, Personal Care Products, Therapeutic – Collection: 5269

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Personal Care Products
  • Therapeutic
  • Healthcare

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5269

License Grant
The Companies today announced a settlement of the patent infringement lawsuit that was filed in 1999 on Zicam Cold Remedy.
License Property
Zicam Cold Remedy has become one of the top-selling cold remedies in the country over the past two years and has been clinically proven to reduce the duration of the common cold by an average of 75% when taken at the onset of symptoms.

IPSCIO Record ID: 1593

License Grant
The Company entered into an exclusive agreement for worldwide representation, manufacturing, marketing and distribution rights to a zinc gluconate/glycine lozenge formulation developed by Licensor and patented in the United States, United Kingdom, Sweden, France, Italy, Canada, Germany, and pending in Japan.
License Property
The Cold-Eeze(R) lozenge products are based upon a proprietary zinc gluconate formula which in a clinical study conducted by The Cleveland Clinic has been shown to reduce the severity and duration of the common cold symptoms.

Patent for the use of zinc gluconate to reduce the duration of the common cold (Patent RE 33,465). Licensor is the owner of certain patents for flavoring for zinc supplements for oral use (Patent 4,684,528 and 4,758,439)

IPSCIO Record ID: 2586

License Grant
The Company entered into a licensing agreement with a patent holder relating to the utilization of a nasal spray product in the treatment of symptoms of the common cold.
Field of Use
The field of use relates to the healthcare industry.

IPSCIO Record ID: 167340

License Grant
This agreement is to provide Licensee  with sole and exclusive rights to make, use, and sell various  products, including lozenges, under The Patent by license granted by Licensor.
License Property
The trademarks include 'Cold-Eeze' and 'Cold-Eezer Plus', containing zinc gluconate under license granted.

Cold-Eeze(TM) product is a homeopathic remedy which is subject to regulation by various federal, state and local agencies, including the FDA and the Homeopathic Pharmacopoeia of the United States.

4,503,070:  Method for reducing the duration of the common cold
4,684,528:  Flavor of zinc supplements for oral use

Field of Use
Cold-Eeze(TM) is a patented cold relief lozenge product.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.